In contrast to the well-established PARPi-resistance mechanisms based on restoration of BRCA1/2 pathway functions, we identify an adaptive mechanism driven by PGF-FLT1-AKT signaling that protects Brca1- and Bard1-deficient breast tumor cells from PARPi-induced cell death in-vivo. This evidence concerns the gene FLT1 and breast neoplasm.